http://rdf.ncbi.nlm.nih.gov/pubchem/patent/TW-201242612-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_40573e5325f08c6f85737fbceb02fb84 |
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-06 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K36-07 |
| filingDate | 2011-04-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a9d350336eb81bb4fdaa2d17ee318b03 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f73a47e28802c6b8d135f7412b00d886 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f80a1e7e6b3235339101a6728161a3b6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_07d0ed0ed8e5971849a5e728c545d3ec |
| publicationDate | 2012-11-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | TW-201242612-A |
| titleOfInvention | Prevent and treatment asthma in mice model with FIP-fve |
| abstract | New existing drugs just offer partial relief of symptoms in such disease. The goal of feature is to understand the complicated mechanism of asthma, and develop more effective drugs for suppressing the inflammatory response in asthma. The golden needle mushroom, Flammulina velutipes, and extracts, possess immunomodulatory, anti-tumor, anti-viral, anti-fungal and cholesterol-lowering activities. A major fruiting body protein, designated Fve or FIP-fve, was isolated and very likely plays a significant role in the mushroom's immunomodulating effects. It stimulates mitogenesis of human peripheral lymphocytes and enhances the transcription of interleukin-2 (IL-2), interferon-g (IFN- γ ). Female BALB/c mice, after intraperitoneal ovalbumin (OVA) sensitization on days 1 to 3 and 14, received intranasal OVA on days 14, 17, 21, 24 and Days 27. The mouse asthma model with airway inflammation by airway mucus release and infiltration by eosinophils was set up. The sensitized mice were divided into 2 groups. One group, the sensitized mice will be fed with FIP-fve on days0 to days14 meaning prevention. Another group, the sensitized mice will be fed with FIP-fve on days14 to days28 meaning treatment. In this mouse asthma model, normal saline was used as a positive control. The non-sensitized mice were used as a negative control. The results show that OVA-sensitized mice developed a significant airway inflammatory response that was inhibited by pre- and post treated with FIP-fve. Airway hyperresponsiveness to methacholine was observed in OVA-sensitized mice. Both pre- and post-treated with FIP-fve reversed airway hyperresponsiveness. An increase in IgE, IL-4, IL-10 and a decrease in IFN- γ , TGF- β in bronchoalveolar lavage fluid (BALF) and sera were found in OVA-sensitized mice, but were reversed by both pre- and post- treated with FIP-fve. |
| priorityDate | 2011-04-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 139.